Broker snap: Votrient approval a boost for Glaxo
6th Oct 2009 12:04
GlaxoSmithKline's experimental kidney cancer drug Votrient has been given a unanimous endorsement by the US Food and Drugs Administration, removing some downgrade risk from the stock, broker Panmure Gordon believes. Panmure Gordon has reiterated its 'buy' recommendation and 1400p price target for G
Read moreLondon open: Footsie posts early gains
6th Oct 2009 08:53
Footsie's bright start is fizzling out a little after disappointment over Tesco's half-year profits, despite the surge by the Dow overnight. Australia's decision to raise interest rates has also sparked some caution, It is the first G20 member to do so since the credit curnch really started to bite
Read moreLondon pre-open: Gains likely as Tesco posts figures
6th Oct 2009 07:33
Tesco is likely to be in focus early on after reporting a modest rise in half-year profits. Traders expect Footsie to open up around 22 points. UK supermarket giant Tesco has made £1.42bn in the six month to August and said it is well-placed for the global recovery. Pre-tax profits were up by 1.5%
Read moreGlaxoSmithKline swine flu orders reach 440m
6th Oct 2009 07:08
GlaxoSmithKline has received another 22 orders for a further 149m doses of its H1 N1 swine flu vaccine. The latest orders bring the total number of doses ordered for GSK's pandemic vaccines to 440m. Discussions continue with governments for further supplies, GSK added. First supplies of the vaccin
Read moreSector movers: Drug groups given a boost
28th Sep 2009 12:23
Drug group AstraZeneca is going well on news that it has won another round in its long-running fight against generic competition to bipolar treatment Seroquel. A US appeal court upheld its infringement claim against Sandoz and Teva Pharmaceutical over Seroquel tablets. The other big drug company,
Read moreLondon close: US data sinks Footsie
24th Sep 2009 16:46
Footsie turned down sharply in the last couple of hours of trading as US shares retreated on weak home sales and lower commodity prices, especially oil. Property companies led the UK lower after Canary Wharf property owner Songbird announced it would issue 62bn shares at a penny each as part of a
Read moreLondon afternoon: Property stocks a drag
24th Sep 2009 15:03
After spending the lunchtime session in positive territory the Footsie has fallen back into the red, with property companies leading the way down. Land Securities, British Land, SEGRO and Hammerson are all under the cosh as investors cool on the sector following huge cash calls this week by Liberty
Read moreLondon midday: Footsie rally falls short
24th Sep 2009 12:22
Footsie still sits in the red after giving up an attempt to launch a foray into positive territory. London Stock Exchange is the heaviest faller after it said the average daily value traded on its SETS electronic trading system declined by 43% in the five month ended August. 3i is also down. The p
Read moreSector movers: Mining rally stops for breath
21st Sep 2009 11:32
Mining stocks have run into profit taking amid weakness in the metals markets. The sector posted good gains last week in line with growing optimism over the prospects for global economic recovery. Even Antofagasta, upgraded today to 'buy' from 'neutral' in a Goldman Sachs mining sector review, is
Read moreSector movers: Chemical sector reacts to Johnson Matthey downgrade
14th Sep 2009 14:00
Johnson Matthey is helping drag the chemicals sector lower. The platinum refiner and catalytic converter maker was downgraded to 'equal-weight' from 'overweight' at Morgan Stanley. Elsewhere in chemicals, Plant Health Care falls back slightly after depressed agricultural markets resulted in widenin
Read moreBroker tips: Glaxo, Go Ahead, Modern Water
9th Sep 2009 13:08
The Centers for Disease Control and Prevention (CDC) issued new guidelines for the use of antivirals in the treatment of flu on Tuesday, which should boost revenues drugs giant GlaxoSmithKline (GSK) receives from its Relenza flu treatment. The ruling that Tamiflu and Relenza should promptly be give
Read moreBroker snap: Glaxo appeals to risk-averse investors
9th Sep 2009 12:57
The Centers for Disease Control and Prevention (CDC) issued new guidelines for the use of antivirals in the treatment of flu on Tuesday, which should boost revenues drugs giant GlaxoSmithKline (GSK) receives from its Relenza flu treatment. The ruling that Tamiflu and Relenza should promptly be give
Read moreBroker tips: HSBC, British Land, Glaxo
18th Aug 2009 12:55
Global banking giant HSBC is in pole position among banks to benefit from the global economic recovery when it picks up steam, Goldman Sachs believes. Goldman Sachs (GS) said that with the chapter now closed on HSBC's ill-fated acquisition of US sub-prime lender Household, its HSBC Finance division
Read moreBroker snap: Glaxo unfazed by Arzerra setback
18th Aug 2009 11:53
Shares in drugs giant GlaxoSmithKline bore up well on Tuesday morning despite disappointing clinical data relating to Arzerra, the blood cancer treatment it has licensed from Danish developer Genmab. Broker Panmure Gordon does not believe the stock will suffer many downgrades as a result of the cli
Read moreTuesday newspaper round-up: British Land, Northern Rock, LSE
18th Aug 2009 06:09
Blackstone, the American private equity group, is set to buy half of the Broadgate Estate in the City of London from British Land. The deal could be announced as early as today when British Land discloses its results for the three months to June 30, which are expected to show a further fall in asset
Read more